MedTrace Logo

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

NCT00348686 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2012-04-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.

Conditions

Interventions

DRUG

Candesartan

16 mg once daily in oral tablet form

DRUG

Candesartan

32 mg once daily in oral tablet form

DRUG

Felodipine

5 mg once daily in oral tablet form

DRUG

Felodipine

10 mg once daily in oral tablet form

Sponsors & Collaborators

Principal Investigators

  • JeeWoong Son, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00348686 on ClinicalTrials.gov